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Background: Multiple sclerosis is a relatively rare disease, and complications of multiple sclerosis and rheumatoid
arthritis are much rarer. Since anti-tumor necrosis factor therapy increases exacerbations of multiple sclerosis,
complications of demyelinating diseases contraindicate anti-tumor necrosis factor therapy. There have been
few reports of anti-interleukin-6 receptor therapy for patients with rheumatoid arthritis complicated with multiple
sclerosis.
Case presentation: A 53-year-old Japanese woman with multiple sclerosis and rheumatoid arthritis was admitted to
our hospital because her rheumatoid arthritis was uncontrolled with oral methotrexate, tacrolimus, and prednisolone.
She had developed multiple sclerosis when she was 25 years old and was treated with glucocorticoid therapy. Her
multiple sclerosis was in remission for more than 9 years. Because anti-tumour necrosis factor therapy can exacerbate
demyelinating disease, the anti-interleukin-6 receptor antibody tocilizumab was started at 8 mg/kg every 4 weeks. At
the second administration of tocilizumab, complete remission was achieved. She has remained in remission with
tocilizumab without recurrence of multiple sclerosis for more than 5 years.
Conclusion: Anti-interleukin-6 therapy was safely used in this patient with rheumatoid arthritis without exacerbations
of multiple sclerosis.
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Multiple sclerosis (MS) is an autoimmune, inflammatory,
demyelinating disease of the central nervous system
characterised by repeated relapses and remissions. The
prevalence rate of MS in Japan is reportedly 8 to 9 per
100,000 persons. High-dose glucocorticoid therapy is
used for initial and relapsed progression of MS with or
without immunosuppressive agents. Although MS is an
autoimmune inflammatory disease, as is rheumatoid
arthritis (RA), and although the level of tumour necrosis
factor (TNF) in cerebrospinal fluid is correlated with the* Correspondence: hiroe-212@umin.ac.jp
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unless otherwise stated.severity and progression of the disease [1], anti-TNF
therapy fails and actually increases exacerbations [2,3].
Therefore, complications of demyelinating diseases con-
traindicate anti-TNF therapy. There have been few re-
ports of anti-interleukin (IL)-6 receptor therapy for
patients with RA complicated with MS.
We herein describe a patient with RA and MS treated
with anti-IL-6 receptor therapy.Case presentation
A 53-year-old Japanese woman was admitted to Niigata
Rheumatic Centre, Shibata city, Japan. She had been
diagnosed with MS associated with right optic neuritis
and thoracic myelitis when she was 25 years old and
treated with high-dose prednisolone (PSL). The myelitis
had relapsed three times when she was 36, 37 and
40 years old and treated with high-dose PSL. Oligoclonald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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IgG and myelin basic protein in CSF were elevated
(4.9 mg/dL and 1.2 mg/dL, respectively). Brain T2
weighted magnetic resonance imaging (MRI) showed
high intensity area beside left lateral ventricle indicating
asymptomatic plaque lesion due to MS. High intensity
area was also shown in T2 weighted MRI of cervical
spinal cord. Anti-aquaporin 4 antibody was negative.
Slight right hemiparesis remained, and she needed a
cane to walk outside. The MS achieved remission and
PSL was stopped for 9 years. When she was 50 years
old, polyarthritis developed, and rheumatoid factor and
C-reactive protein (CRP) levels were high. She was diag-
nosed with RA. The PSL was restarted at 7.5 mg daily
and methotrexate (MTX) was begun. Because the MTX
could not be increased over 8 mg/week because of mild
elevation of transaminases, tacrolimus (3 mg daily; TAC)
was added to MTX and leukocyte apheresis was per-
formed. However, the RA activity remained high: the
CRP was 2.3 mg/dL and the disease activity score
(DAS28ESR) was 4.94 (moderate disease activity). Fur-
thermore, joint space narrowing of both knees and
ankles had progressed obviously over 1 year. Because
anti-TNF therapy can exacerbate demyelinating disease,
the anti-IL-6 receptor antibody tocilizumab (TCZ) was
started at 8 mg/kg every 4 weeks. At the second admin-
istration of TCZ, the CRP was <0.1 mg/dL and the
DAS28ESR was 2.0 (complete remission). The MTX and
TAC were tapered and stopped in 6 months, and the
PSL was tapered to 0.5 mg daily in 1 year. The health
assessment questionnaire disability index (HAQ DI) in
1 year was 1.88 and functional disability was remained.
At the 5-year follow-up, she remained in remission
with TCZ.
Serum interferon (IFN) -γ was negative (≤0.1 IU/mL)
and serum high sensitivity TNF-α was within normal
range (1.6 pg/mL) before starting TCZ therapy. Both of
them kept the same levels for a year. Serum IL-6 level
was elevated, 51.2 pg/mL (normal range; ≤4.0 pg/mL)
before starting TCZ therapy and it was 57.1 pg/mL a
year later.
Discussion
Complications of MS and RA are rare, and only a few
cases have been reported [4,5]. In two case reports, the
duration between the onset of each disease was long
(8–20 years), and RA or MS was preceded by the other
and the two diseases did not flare at the same time [4,5].
Our patient with MS also developed RA 25 years after
the onset of MS, which was well controlled without
medication for 9 years. Thus, the onset mechanisms of
MS and RA are expected to fundamentally differ
despite the fact that both are autoimmune inflam-
matory diseases.On the other hand, there are several reports of pa-
tients with RA who developed demyelinating diseases
during anti-TNF therapy [6-8] and patients with MS
who developed inflammatory arthritis during IFN-β
therapy [9,10]. The mechanisms of demyelinating disease
induced by anti-TNF therapy are not clear, but inhibition
of TNF leads to IFN-γ production, which is associated
with MS [11]. Moreover, TNF polymorphism may be as-
sociated with anti-TNF therapy-induced demyelinating
diseases [12]. IFN-β therapy for preventing recurrence of
relapsing-remitting MS and secondary progressive MS is
now widely used. Arthritis reportedly develops during
IFN-β therapy in patients with MS, and the HLA pheno-
type may be involved in its pathogenesis [9]. Elevated
levels of IL-6 in the serum in response to IFN-β therapy
may also be associated with arthralgia [10].
In comparison, few studies have reported anti-IL-6 ther-
apy in demyelinating disorders. A case report of a 72-year-
old woman with leukoencephalopathy that developed in a
Phase 3 clinical trial of TCZ for treating RA has been pub-
lished [13]. However, the relationship between TCZ and
leukoencephalopathy was not clear because the possibility
of infection had not been completely excluded and the
symptoms did not improve after discontinuing TCZ.
Studies involving mouse models of MS (experimental
autoimmune encephalomyelitis, EAE) and RA (collagen-
induced arthritis, CIA) have revealed that Th-17 plays
an important role in the development of both diseases
[14,15]. Furthermore, IL-6 mainly affects the differen-
tiation of Th-17 in the mouse, and anti-IL-6 therapy in-
hibits the onset of EAE and CIA. Meanwhile, TNF
affects local inflammation [14,15]. Thus, anti-IL-6 the-
rapy may control EAE and CIA earlier and more radic-
ally than anti-TNF therapy. In humans, IL-6 mainly
affects the differentiation of Th-17, as in the mouse, and
anti-IL-6 therapy should theoretically inhibit both RA
and MS. However, the cytokine pathways differ in
humans and mice, and further studies are needed to de-
termine whether anti-IL-6 therapy can be used safely in
patients with MS.
Conclusion
Here, we reported a patient with RA complicated by MS
who was treated with anti-IL-6 therapy for more than
5 years without an exacerbation of the MS. Because
anti-TNF therapy can induce and worsen demyelinating
diseases, anti-IL-6 therapy is a potential treatment for
patients with RA complicated by MS.
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